Recruiting
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL
NCT04908228
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
- Locations
-
- Strategic Research Program on CLL Milan, MI, Italy